3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
2
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Triple Negative Breast Neoplasms
7
Breast Neoplasms
6
Lung Neoplasms
5
Ovarian Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Neoplasms
2
Medulloblastoma
2
Fallopian Tube Neoplasms
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Thymic epithelial tumor
1
Thrombocythemia, Essential
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Squamous NSCLC
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Retinoblastoma
1
Recurrence
1
Primary Myelofibrosis
1
Primary Malignant Neoplasm of Ovary
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Paclitaxel
2
Letrozole
1
Lapatinib
1
Gonadotropin-Releasing Hormone
1
Doxorubicin
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Ductal, Breast
×
Carboplatin
×
Clear all
NCT01426880
2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3
Completed
595 enrolled